Literature DB >> 6849408

Differential effect of verapamil isomers on sinus node and AV junctional region.

H O Gloor, F Urthaler.   

Abstract

The l- and d-isomers of verapamil were selectively perfused into the sinus node artery and atrioventricular (AV) node artery of 48 dogs. Injection of l-verapamil into the sinus node artery during sinus rhythm and into the AV node artery during AV junctional rhythm depresses both sinus rhythm and AV junctional rhythm significantly more than does the d-isomer. l-Verapamil is three to four times more powerful than d-verapamil. Injection of the isomers into the AV node artery during sinus rhythm rapidly impairs AV conduction. Increments in conduction time are measured exclusively at the level of the A-H interval of the His bundle electrogram, and l-verapamil is six times more powerful than d-verapamil. Neither d- nor l-verapamil in concentrations that exert a profound negative chronotropic effect or cause AV block, has any significant effect on transatrial or His bundle conduction. Thus these concentrations of d-verapamil have little or no significant effect on the fast sodium channel, but both verapamil isomers affect the slow channel. The main difference in action between l- and d-verapamil appears to be only quantitative in nature. The sinus node is significantly more sensitive to the negative chronotropic action of verapamil than is the AV junctional pacemaker, and this differential responsiveness appears to be related to the different intrinsic rates of the two pacemakers. During sinus rhythm (either in the presence or absence of atropine) sinus node automaticity is less affected than AV conduction when verapamil is given parenterally. We propose that this greater negative dromotropic effect of verapamil is also in part due to a rate-dependent process, since during sinus rhythm AV junctional cells have to be depolarized at frequencies significantly higher than their intrinsic rates.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849408     DOI: 10.1152/ajpheart.1983.244.1.H80

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

1.  Randomised trial of vindesine and etoposide +/- dexverapamil in advanced non-small cell lung cancer: first results.

Authors:  U Gatzemeier; A Schneider; J von Pawel
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  Biphasic dose-response relationship observed with Bay k 8644 on atrioventricular nodal conduction inhibited by verapamil.

Authors:  J Lang; Q Timour; J P Lançon; J F Aupetit; G Faucon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

3.  Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.

Authors:  Dagmar Busse; Silke Templin; Gerd Mikus; Matthias Schwab; Ute Hofmann; Michel Eichelbaum; Kari T Kivistö
Journal:  Eur J Clin Pharmacol       Date:  2006-07-04       Impact factor: 2.953

4.  Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study.

Authors:  Raffaele Coppini; Cecilia Ferrantini; Josè Manuel Pioner; Lorenzo Santini; Zhinuo J Wang; Chiara Palandri; Marina Scardigli; Giulia Vitale; Leonardo Sacconi; Pierluigi Stefàno; Laura Flink; Katherine Riedy; Francesco Saverio Pavone; Elisabetta Cerbai; Corrado Poggesi; Alessandro Mugelli; Alfonso Bueno-Orovio; Iacopo Olivotto; Mark V Sherrid
Journal:  JACC Basic Transl Sci       Date:  2019-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.